ArticleAntibodies (Basel, Switzerland)2016

Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer.

Adam R Root et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.